Kyowa Hakko Kogyo Co., Ltd. Completes Overseas Phase III Clinical Trials For KW-6002, Anti-Parkinson's Disease Agent
08 Mar 2006
Tokyo, Mar 8, 2006 (JCN) - Kyowa Hakko Kogyo has completed three phase III clinical trials for KW-6002, its investigational drug for treating Parkinson's disease; two were conducted in North America and one in Europe. KW-6002 is a promising agent that selectively antagonizes the adenosine A2A receptor.
Organizations
Indications
Targets
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.